he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
上一页:导致癫痫病的疾病都有什么
下一页:一文掌握癫痫用药22集
- 2022-04-252013年国际抗癫痫联合会抗癫痫制剂使用指南
- 2022-04-21癫痫病的常见患病因素有什么
- 2022-04-05FDA批准Aptiom用于治疗患者癫痫发作
- 2022-04-04全球干细胞临床试验1000多项,在白癜风领域潜力巨大
- 2022-02-14对人早期癫痫病症状能治疗吗
- 2022-02-07成年人为什么会患癫痫病 癫痫病症状
- 中华医学会系列精选指南|急性腹痛、淋巴瘤、银屑病的诊断和治疗
- 自身免疫病也可以免疫治疗
- 焦虑和疾病认知影响银屑病关节炎患者的健康生活量表
- 疾病新知:毛囊性白癜风
- 注射激素会导致外周色素减少和萎缩
- FDA批准Aptiom用于治疗患者癫痫发作
- 全球干细胞临床试验1000多项,在白癜风领域潜力巨大
- 诺华Cosentyx欧盟批准治疗中重度斑块状银屑病
- 导致皮肤问题的原因有六个
- 喝茶对白癜风有什么影响?
- 广西百色破获药案:涉及74家药店,3000多盒
- 预测癫痫患者再入院风险
- 白癜风饮食治疗方法是什么?
- 手足口病的初始症状 手足口病的表现是什么?
- 晚餐吃什么减肥?这样吃饭很容易减肥
- 抗癫痫药物预防新发癫痫:任重而道远
- 白癜风光疗有很多方法 因地制宜教你选择
- 专家回答,如何诊断儿童白癜风?
- 月经期间要注意 有些药物和食物不能食用
- 如何预防白癜风?!
- 综述:癫痫持续状态诊治最新进展
- 中医如何治疗癫痫 癫痫预防?
- 原发性小肠淋巴管扩张症一例
- 女性癫痫的治疗多少钱
- 白癜风病愈后如何巩固防复发?
- 延迟性癫痫患者中风预后较差
- 为什么光疗能有效治疗白癜风?
- 癫痫病的症状及疗程
- 昭和年间癫痫病能昭和年间的好么
- 患上癫痫病要怎么患病呢
- 癫痫病患病究竟是怎么回事
- 前瞻性科学研究表明癫痫与卒中之间存在联系
- 先天性癫痫病的疾病有哪些
- 正因如此「利」控制 升级保护——利必通®分散片中国上市会
- 怎么治疗癫痫病效果相比较好
- 癫痫病怎样治果会好
- 国际当前研究:莫扎特音乐或对耐药性癫痫有治疗潜力
- 癫痫病肉什么可以控制
- 卫材在荷兰推出新一代抗癫痫药Fycompa
- 癫痫病的哮喘是哪些因素影响的呢